Randomized Withdrawal Study in Patients With Schizophrenia
Recruiting
Phase 3
Interventional Study
Schizophrenia
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 400 (estimated)
- Sponsor
- Vanda Pharmaceuticals · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Males or females 18 to 65 years of age (inclusive)
* Diagnosed with schizophrenia per DSM-5 criteria
* In need of ongoing psychiatric treatment
Exclusion Criteria:
* DSM-5 diagnosis of a psychiatric disorder other than schizophrenia that was the primary focus of treatment wi…
Contacts